Introduction to the DRIVE-SWITCH Study

Clinicians frequently seek to simplify antiretroviral therapy (ART) for patients living with HIV. The B/F/TAF switch HIV strategy offers a potent, single-tablet option for those currently managed on NNRTI-based regimens. Recently, the DRIVE-SWITCH study evaluated the effectiveness of this transition in virologically suppressed individuals. This retrospective analysis provides valuable real-world evidence for modern HIV management, especially for patients transitioning from rilpivirine (RPV).

Clinical Benefits of the B/F/TAF Switch HIV Strategy

The study analyzed 250 people with HIV (PWH) who were already virologically suppressed on NNRTI triple therapy. Most participants transitioned from rilpivirine-based regimens. Because maintaining suppression is critical, the researchers monitored outcomes over 12 months. Results showed that 95.2% of patients with available data maintained viral suppression. Furthermore, the mean CD4+ T-cell count increased by 52 cells/mm³ during the follow-up period. Consequently, the switch appears both effective and immunologically beneficial for clinical practice.

Safety and Treatment Durability

Adverse events leading to treatment discontinuation were remarkably rare in this cohort. Only 1.6% of participants stopped the regimen due to issues such as insomnia, mood disorders, or epigastric pain. Additionally, no new resistance mutations emerged during the study period. This is significant because a high genetic barrier to resistance is a hallmark of second-generation integrase inhibitors. Therefore, this single-tablet regimen serves as a durable alternative for long-term maintenance in suppressed patients.

FAQs

Why consider a B/F/TAF switch HIV strategy?

Switching to B/F/TAF simplifies treatment by providing a single-tablet regimen. It offers a high genetic barrier to resistance and typically improves tolerability compared to older NNRTI regimens.

What were the virologic outcomes in the DRIVE-SWITCH study?

Approximately 95.2% of patients with available 12-month follow-up data maintained an HIV-RNA level of less than 50 copies/mL after switching.

Is the switch safe for patients on rilpivirine?

Yes, the study specifically included many patients switching from rilpivirine-based regimens and found high efficacy with very few treatment discontinuations.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Gagliardini R et al. Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study). Infect Dis Ther. 2026 Mar 19. doi: 10.1007/s40121-026-01330-7. PMID: 41854855.

European AIDS Clinical Society (EACS). Guidelines Version 13.0. October 2025.

CDC. Clinical Care of HIV: Antiretroviral Therapy. February 2025.